UK – Transition Bio, Inc., a Cambridge, MA- and Cambridge, UK-based provider of a microfluidics-driven drug discovery platform using biophysical sciences and artificial intelligence tools to map and modulate biomolecular condensates, raised $50m in Series A financing.
The round was led by Northpond Ventures and joined by Taiho Ventures, Bristol Myers Squibb and Magnetic Ventures. Lifeforce Capital, the lead investor from the seed financing, also participated and was joined by other existing seed investors. Led by Greg Miller, chief executive officer, Transition Bio is a provider of a microfluidics-driven drug discovery platform that utilizes microfluidics to drive high-throughput generation of proprietary data to enable machine learning-guided condensate target identification and drug discovery. The funding allows rapid expansion of the technology by scaling up the platform and translating the science across a variety of targets and disease areas.In addition, Shilpi Arora, Ph.D., joined Transition Bio as senior vice president of discovery research and brings extensive experience in leading multiple aspects of drug discovery, target identification and validation, pharmacology and translational sciences from previous roles in both academia and the biotech industry. Prior to joining Transition Bio, Shilpi was vice president of discovery and translational biology at Exo Therapeutics and previously held roles at X-Chem Pharmaceuticals, Constellation Pharmaceuticals and the Translational Genomics Research Institute.Transition Bio also announced updates to its board of directors. Shaan C. Gandhi, M.D., D.Phil., director and head of the biotechnologies group at Northpond Ventures, has been appointed to the Company’s board. In addition, Alfred W. Sandrock, Jr., M.D., Ph.D., chief executive officer of Voyager Therapeutics and former head of research and development at Biogen, has been appointed to the board as an independent director. Co-founders Kelly Martin and Samuel Cohen, Ph.D., will continue to serve on the board as executive chairman and director, respectively.02/06/2022
